<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methysergide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00247</strong>&#160; (APRD00463)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An ergot derivative that is a congener of lysergic acid diethylamide.  It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00247/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00247/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00247.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00247.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00247.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00247.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00247.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00247">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>1-Methyllysergic acid butanolamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Methysergidum</td><td>Latin</td><td>INN</td></tr><tr><td>Metisergido</td><td>Spanish</td><td>INN</td></tr><tr><td>N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methysergide maleate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000895/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000895/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000895">DBSALT000895</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Deseril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Desernil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sansert</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasoconstrictor-agents">Vasoconstrictor Agents</a></li>
<li><a href="/mesh/serotonin-antagonists">Serotonin Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>361-37-5</td></tr><tr><th>Weight</th><td>Average: 353.458<br>Monoisotopic: 353.210327123</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>KPJZHOPZRAFDTN-NQUBZZJWSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15?,19-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4R,7R)-N-(1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Quinolines and Derivatives</td></tr><tr><th>Subclass</th><td>Indoloquinolines</td></tr><tr><th>Direct parent</th><td>Indoloquinolines</td></tr><tr><th>Alternative parents</th><td>Benzoquinolines; Quinoline Carboxamides; Pyrroloquinolines; N-substituted Nicotinamides; Indoles; Isoindoles and Derivatives; Tetrahydropyridines; Benzene and Substituted Derivatives; N-methylpyrroles; Tertiary Amines; Secondary Carboxylic Acid Amides; Polyamines; Enolates; Carboxylic Acids; Primary Alcohols; Ergoline Derivatives</td></tr><tr><th>Substituents</th><td>benzoquinoline; quinoline-3-carboxamide; pyrroloquinoline; n-substituted nicotinamide; indole or derivative; isoindole or derivative; indole; tetrahydropyridine; n-methylpyrrole; substituted pyrrole; n-substituted pyrrole; benzene; pyrrole; carboxamide group; secondary carboxylic acid amide; tertiary amine; polyamine; primary alcohol; carboxylic acid; carboxylic acid derivative; enolate; amine; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the indoloquinolines. These are polycyclic aromatic compounds containing an indole fused to a quinoline.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of vascular headache</td></tr><tr><th>Pharmacodynamics</th><td>Methysergide has been shown, <i>in vitro</i> and <i>in vivo</i>, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a "headache substance" acting directly or indirectly to lower pain threshold, as an intrinsic "motor hormone" of the gastrointestinal tract, and as a "hormone" involved in connective tissue reparative processes.</td></tr><tr><th>Mechanism of action</th><td>Methysergide is serotonin antagonists acts on central nervous system (CNS), which directly stimulates the smooth muscle leading to vasoconstriction. Some alpha-adrenergic blocking activity has been reported. Suggestions have been made by investigators as to the mechanism whereby Methysergide produces its clinical effects, but this has not been finally established, although it may be related to the antiserotonin effect.</td></tr><tr><th>Absorption</th><td>Rapid</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Few cases of acute methysergide intoxication have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. Euphoria, hyperactivity, tachycardia, dilated pupils, and dizziness have been reported in a child with a dose of 20-24 mg of methysergide. In adults, peripheral vasospasm, with diminished or absent pulses, coldness, mottling and cyanosis, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with methysergide.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7015</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8064</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8396</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7515</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8129</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8536</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8474</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6889</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.791</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9161</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5241
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8906
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8144
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.3039 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9569
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6274
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.novartis.com">Novartis AG</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li>Professional Co.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01612">Amyl Nitrite</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Risk of ergotism and severe ischemia with this association</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01613">Erythrityl Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00883">Isosorbide Dinitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01020">Isosorbide Mononitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Possible severe and prolonged vasoconstriction.</td></tr><tr><td><a href="/drugs/DB00727">Nitroglycerin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB06154">Pentaerythritol Tetranitrate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Contraindicated co-administration</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Risk of ergotism and severe ischemia with this association</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Possible severe and prolonged vasoconstriction</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>